Transfusion-related acute lung injury (TRALI) is suggested to follow a 'two-hit' mechanism. The 'first hit' is the underlying condition of the patient (e.g. sepsis) resulting in priming of neutrophils and/or endothelium. The 'second hit' is any transfusion resulting in activation of the primed neutrophils and/or endothelium. The transfusion factors can be divided into antibody-mediated and non-antibody-mediated TRALI. Antibody-mediated TRALI is caused by passive infusion of donor antibodies reacting with the cognate antigen of the recipient. Non-antibody-mediated TRALI is thought to be caused by the transfusion of stored cellular blood products. Although the mechanisms involved in antibody-mediated TRALI have been well outlined and confirmed in preclinical and clinical studies, this is not the case for non-antibody-mediated TRALI. Preclinical studies show a strong association between storage time of cellular blood products and the onset of lung injury. However, recent clinical studies show contradictory results. In this review, the latest insights on the pathogenesis of non-antibody-mediated TRALI will be discussed as well as the areas future research should be focused on.
Introduction
Transfusion-related acute lung injury (TRALI) is a syndrome of respiratory distress caused by transfusion of blood products. It is a major cause of transfusion-related mortality [1] . The term TRALI was first coined by Popovsky in 1983 [2], but it was not until 2004 that an internationally accepted TRALI definition was formulated. Since then, TRALI is defined as onset of acute lung injury (PaO2/ FiO2 < 300 mm Hg, or worsening of P-to-F ratio) within 6 h of blood transfusion and bilateral infiltrates on the chest X-ray. No additional risk factor for acute lung injury may be present and TRALI can only be diagnosed in the absence of hydrostatic pulmonary oedema (Table 1) [3] [4] [5] . TRALI closely resembles ARDS and patients develop symptoms of dyspnoea, fever, hypotension and sometimes hypertension, hypoxia, passing leucopenia and thrombopenia. Post-mortem examinations on patients who die of TRALI reveal pulmonary oedema, diffuse alveolar damage, hyaline membrane formation and extensive granulocyte infiltration and aggregation in the alveoli [6, 7] . The reported TRALI incidence varies between 0Á08 and 15Á1% per patient transfused and 0Á01 and 1Á12% per product transfused [8, 9] . In particular, critically ill patients bear an increased risk for developing TRALI after blood transfusion [10, 11] which can be explained in the light of the 'two-hit hypothesis' and the 'threshold model'. In the 'two-hit' model, a 'first hit', a severe underlying clinical condition of the patient as for example sepsis, causes priming of the pulmonary neutrophil and migration to the pulmonary vasculature. The 'second hit', the transfusion of red blood cells (RBCs), platelets (PLTs) or plasma, causes activation of the neutrophils in the pulmonary compartment resulting in TRALI [10, [12] [13] [14] [15] [16] . Patient and transfusion risk factors combined result in an accumulated risk to develop TRALI which is described with the 'threshold model'. Only when the combined patient and transfusion product risk factors pass a certain 'threshold', the patient develops TRALI [17] . Approximately 50-80 per cent of TRALI cases have been related to the infusion of human leucocyte antigen (HLA) or human neutrophil antigen (HNA) antibodies from the donor blood [18] [19] [20] . In these cases, antigen-antibody interaction led to activation of primed neutrophils, socalled antibody-mediated TRALI [18, 21] . It should be noted however that a recent study using more sensitive bead-based assays identified TRALI cases with incompatible antibodies which were missed with the commonly used, but less sensitive, cellular-based assays [20] . However, still not in all cases, fulfilling the clinical definition of TRALI antibodies could be detected [22] [23] [24] and recipients of a product which contains antibodies do not always develop TRALI, even in the presence of the cognate antigen [25] .
This resulted in the hypothesis of non-antibodymediated TRALI for the remaining 20-50% of TRALI cases. This review provides an update on evidence on the pathogenesis of non-antibody-mediated TRALI.
TRALI pathogenesis
Our knowledge of TRALI pathogenesis is mainly derived from in vitro and animal studies. TRALI is thought to be mediated by neutrophils. During the 'first hit', the pulmonary endothelium release cytokines and chemokines which facilitate neutrophil migration to the lung. There, selectins and other adhesion molecules mediate adhesion of the neutrophils to the endothelium. The transfusion product activates these neutrophils, and the cells migrate into the air space where they release oxidants and proteases. The air space is filled with protein-rich oedema which causes the clinical symptoms of acute respiratory distress [26] . However, recent studies have demonstrated that it is not solely dependent of activation of neutrophils as lung injury can also develop through direct activation of endothelium and by interaction with monocytes [27] [28] [29] . Moreover, neutropenic patients can develop TRALI [30] and histochemical colouring of lung sections of patients who died of TRALI do not always show neutrophils in the alveolar space [31] .
It
is not yet known which factors in the transfusion product induce non-antibody-mediated TRALI. The past years' research has focused mainly on pro-inflammatory mediators which can accumulate in stored transfusion products and on the effect of storage time of transfusion products [8, 9] . We will describe which factors have been investigated in relation to TRALI in the past years.
Research on TRALI pathogenesis
Developments in the past years
RBC storage lesion
Post-transfusion recovery and function is influenced by the storage duration of the transfusion product. Therefore, to ensure sufficient post-transfusion function, most countries have limited storage of RBCs to 35-42 days [32] . During storage, RBCs undergo changes referred to as the 'storage lesion'. The RBC suffers vesiculation, membrane loss and lysis, reduced superoxide oxygen scavenging properties, resulting in oxidation of lipids and proteins, depletion of 2,3-diphosphoglycerate, reduction of adenosine triphosphate and nitric oxide and decreased membrane expression of CD47 [33] . These processes are accompanied by storage-dependent decrease in pH, increase of potassium and loss of haemoglobin.
Transfusion has been related to a number of serious adverse events, including increased infections, pulmonary oedema, acute coronary syndrome and increased hospital length of stay [33] [34] [35] [36] . Several observational studies have associated storage time of transfusion products with increased morbidity and mortality [37, 38] .
The role of RBC storage time in TRALI has been studies extensively with various in vitro, ex vivo and in vivo animal models [8] . In the animal models, aged RBCs were clearly related to TRALI which is supported by a prospective study in humans [16] . However, other observational studies did not detect an association between storage time and TRALI [10, 14, 15, 39] . Recently, the first human 'two-hit' transfusion model has been published [40] . In this study, human volunteers were primed with lipopolysaccharide as 'first hit'. This was followed by either autologous fresh or autologous stored RBCs as 'second hit'. This model eliminated limitations of the animal models: many models suffer from interspecies confounding and animal blood product deteriorates earlier compared to human products [41] . It also eliminated confounding factors of the observational studies as patients received both old and fresh transfusion products, standard transfusion practice uses allogeneic transfusion products which preclude investigation of storage time, and the studies' populations reflected a heterogeneous patient group. In this model, maximally stored RBCs did [40] . Due to the relatively low incidence of TRALI, performing a prospective randomized trial in patients to specifically investigate the effect of storage time on TRALI incidence would be difficult. However, two large randomized controlled trials (RCTs) have compared the effect of fresh blood to standard stored time blood on mortality and morbidity. The recently published Age of Blood Evaluation (ABLE) trial investigated whether fresh allogeneic RBCs (stored <8 AE 4Á9 days, n = 1211) would reduce adverse effect compared to standard stored allogeneic RBCs blood (mean storage time 22 AE 8Á4 days, n = 1219) in critically ill patients. This study did not show that fresh RBCs are superior to stored RBCs on organ failure (e.g. ARDS), 90-day survival, incidence of major illnesses, duration of respiratory, hemodynamic or renal support, length of stay in the hospital or transfusion reactions. The Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery (RECESS) study had a similar design and investigated the effect of fresh allogenic RBCs (stored ≤10 days, n = 538) compared to standard issued, stored allogeneic RBC (storage ≥21 days, n = 560). Fresh RBCs have no effect on the multiple organ dysfunction score or mortality [42] . One must bear in mind that these studies and two smaller studies did not compare maximally stored RBCs to standard stored RBCs [43] [44] [45] . Nevertheless, most evidence now indicates that storage time is unrelated to complications of red blood cell transfusion [46] .
Bioactive lipids
Bioactive lipids accumulate in transfusion products during storage. It has been hypothesized that these lipids can induce TRALI in the recipient [7, [47] [48] [49] [50] [51] [52] [53] [54] . The past decades' research has focused on a subset of both the polar and non-polar lipids which have been implicated in TRALI [8] . The polar lipids of interest have been identified as lysophosphatidylcholines (LysoPCs), lipids structurally similar to platelet-activating factor (PAF) and to the ligand for the G2A receptor [7, 54] . These lipids accumulate in both RBCs and PLTs and cause chemotaxis and release of components of the microbicidal arsenal by activation of the G2A receptor on neutrophils [55, 56] . The non-polar lipids have been identified as arachidonic acid, 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE and 15-HETE [57] . Non-polar lipids accumulate in RBCs but not in PLTs. Polar lipids accumulate to a lesser extent in leucoreduced products in which PLTs content decrease by 4-5 logs than in non-leucoreduced RBCs. Therefore, LysoPCs are thought to be platelet derived and arachidonic acid, 5-HETE, 12-HETE and 15-HETE to be RBC derived [57, 58] .
The role of these in TRALI is still debated. The first report that implicated LysoPCs in TRALI was from a series of 10 patients suffering TRALI [23] . This was followed by various animal studies. In ex vivo animal studies originating from the USA, supernatant from outdated but not fresh RBCs caused lung injury and the LysoPCs isolated from these aged blood products also caused evident lung injury [7, 49] . These findings were confirmed in vivo when rats developed acute lung injury after injection with either supernatant of aged RBCs or with LysoPCs, again isolated from the stored products [47] . However, three other groups could not confirm that lipids play a role in in vivo transfusion models. LysoPCs did not accumulate in stored RBCs and were only slightly elevated in aged PLTs [50, 51, 58, 59] . Moreover, a study investigating the origin of LysoPCs concluded that these lipids are not cell derived, but originate from the plasma component and that neutrophil priming was LysoPC independent. In this study, accumulation was storage temperature dependent as opposed to storage time related [58, 60] . Clinical studies also report conflicting results on the role of LysoPCs [10, 16, 60, 61] Two animal studies focused on the role of non-polar lipids in TRALI. In these studies, non-polar lipids from stored RBCs caused acute lung injury [57] and filtration of the transfusion products before storage prevented TRALI [48] . The role of non-polar lipids in human TRALI has not been explored yet and needs further investigation. However, the difference in results from USAbased studies and European/Asian studies has led to the hypothesis that the role of bioactive lipids is dependent of the production process and storage procedures of blood products. Studies in which LysoPCs were implicated in TRALI originate from the United States whereas the studies where no role was found for LysoPCs come from either Europe or Asia [10, 13, 14, 16, 50, 51, 58, 60]. It has also been hypothesized that production of bioactive lipids might be influenced by donor characteristics and not storage time [62] .
Soluble CD40L
Soluble CD40L (sCD40L) accumulates in stored platelets and has been associated with transfusion reactions [63] . CD40 is a member of the tumour necrosis factor (TNF) receptor family expressed on, amongst other types, endothelial cells and monocytes. Its ligand CD40L is produced by platelets and is a pro-inflammatory mediator [64] [65] [66] . Inhibition of the CD40-CD40L system attenuates lung injury in in vivo animal models [61, 67] . In vitro sCD40L containing transfusion products decreases viability of human microvascular endothelial cells (HMVEC) [65] . However, in vivo, both sheep and rats developed lung injury after transfusion of stored platelets with low levels of sCD40L [50, 68] . One clinical study reported higher concentrations of sCD40L in platelets transfused to patients developing TRALI compared to control platelets [65] . On the other hand, in a cohort of prospectively included patients, no elevated sCD40L was found in the group that developed TRALI [69] . Even though sCD40L is a potent mediator in inflammation, a majority of studies suggest only a minor role for sCD40L in TRALI.
Future research focus
Several research groups work on unravelling the pathogenesis of TRALI. However, in recent years, focus has shifted somewhat from identifying which factors in transfusion blood is responsible for the 20-50% of non-antibody-mediated TRALI cases to identification of cellular pathways that are responsible for pulmonary damage in antibody-mediated TRALI [8, 9, 70-72]. However, several in vitro and in vivo studies have indicated that storage time of platelets and donor-derived factors might be related to TRALI and other transfusion-related morbidity.
Storage time of platelets
Similar to the stored RBC, the stored PLT also suffers changes during storage. The PLT changes shape from discoid to spheroid, it shrinks, shows cytoplasm condensation and extension of filopodia, the energy metabolism alters and expression of GPIIIa, GPIIb and P-selectin increases. The platelet storage lesions affect in vivo recovery, survival and haemostatic activity after transfusion [73, 74] . As with RBCs, storage time of platelets has been clearly related to TRALI. [75] [76] [77] [78] and platelets may even be more susceptible to changes in storage procedures and processing than RBCs. For example, experiments with platelets treated with UV-B illumination showed that illuminated aged platelets caused acute lung injury in two-hit murine models [75] [76] [77] [78] . However, a recent study with riboflavintreated, UV-B-illuminated platelets did not replicate these findings [79] . This difference might be attributed to different storage conditions as in the most recent study, PLTs were illuminated in closed bags [79] where before PLTs were illuminated in an open system [75, 77, 78] . The evidence from human studies on the effect of storage time of platelets is not as extensive as for RBCs. Clinical studies report conflicting evidence on the role of storage time [11] . However, all these studies are observational and no prospective randomized trial has investigated the effect of platelet storage time on clinical end-points. A randomized controlled trial with similar design as the ABLE or the RECESS might shed light on the hypothesis that longer stored platelets can have harmful effects in the recipient. However, it is questionable whether such a trial is feasible with a relative short storage time.
Donor factors
In most countries, the supply of transfusion products relies fully on voluntary (mostly non-renumerated) blood donation. The quality of these transfusion products is influenced by characteristics of these donors and some of the measures to prevent TRALI have been aimed specifically at certain donor groups. Well-known interventions aimed at optimizing transfusion products at donor level are the exclusion of previously transfused donors and screening donors with questionnaires to assess infectious risk [21, 80, 81] . The most influential measure to prevent TRALI has been the implementation of male-only plasma for transfusion products [82, 83] . This has reduced the number of TRALI cases with approximately two-thirds. The policy was based on the fact that antibody development occurs most frequently when, during pregnancy, females are exposed to the antigens of their foetus which has inherited the alloantigen from the father. From 1 October 2016, the AABB will implement a new standard to further reduce TRALI. The new guidelines now state that apheresis platelets should now also be donated by males, females who have not been pregnant or females who have had negative HLA antibody test results since their most recent pregnancy [84] . A recent study reported that after implementation of the male-only donor policy for plasma transfusion, apheresis platelet transfusion has the highest risk to induce TRALI. The authors suggest that risk of TRALI from apheresis platelets might be reduced by another 60% by selectively testing female donors who have had prior pregnancies and excluding those with positive results for HLA Class I and II antibodies [85] . Before-and-after studies, as have been performed after implementation of the male-only donor plasma strategy, can identify whether introduction of donor selection for apheresis plasma also results in reduction of TRALI.
Recent investigations indicate that in-bag-haemolysis, ATP levels, metabolic rate, microparticle formation and oxygen transport efficacy show wide interdonor variation.
[86]. Trials have only focused on storage time in general in relation to outcome and did not take into account interdonor variability. It could be hypothesized that blood products from donors that store poor so-called 'bad donors' may induce a TRALI-like syndrome in the recipient. Genetic factors, ABO blood group, lifestyle aspects as diet, alcohol consumption, body weight and smoking, sex, and age have been suggested to influence this variability [87] . Which of these -if any -factors influence the quality of the transfusion product is subject to investigation. In vitro studies demonstrated that the level of haemolysis is increased in products from male donors, in older donors and from donors with higher BMI (abstracts presented at AABB annual meeting in 2015 [88, 89] ).
However, most of the evidence for donor variability originates from in vitro work as little clinical studies have been performed that investigated these factors. The few clinical studies that have investigated the influence of donor characteristics were mostly retrospective and had a high risk of bias. An observational study has looked into the relation between donor sex and recipient sex on mortality. In this study, a sex-mismatched transfusion had a hazard ratio for mortality of 1Á2 (95% confidence interval 0Á98-1Á4) with a larger risk in patients below 55 (hazard ratio 1Á8, 95% confidence interval 1Á2-2Á7) [90] . A recent study has investigated the influence of donor characteristics on platelet transfusion recovery. In this study, healthy volunteers received 5 days stored autologous platelets together with fresh autologous platelets. The platelets were labelled with a radioactive labelled which facilitated isolation from blood samples drawn after transfusion. Metabolomics revealed that, amongst others, caffeine metabolites were associated with poor platelet recovery which implies that modifying donor environment (in this case, donor coffee consumption) can improve transfusion products [91] . Studies like these provide evidence that donor characteristics can have significant impact on the quality of the transfusion product. Whether these factors may also result in products which are able to induce a TRALI-like syndrome remains to be determined.
Conclusion
In approximately 50-80% of TRALI cases, no cognate antibodies can be detected. It has been hypothesized that biological reactive molecules related to product handling and storage are responsible for onset of the remaining 20-50% of cases, so-called non-antibody-mediated TRALI. The past years' research has concentrated on the role of non-polar lipids, RBC storage time and soluble CD40L, but these most likely play a minor role in onset of non-antibody-mediated TRALI. Research on the pathogenesis of non-antibodymediated TRALI now focusses on storage time of platelet products and of donor characteristics which are associated to product quality both in vitro and in vivo. 
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